Facebook link Linked In link You Tube link

The Federation of Clinical Immunology Societies (FOCIS) exists to improve human health through immunology by fostering interdisciplinary approaches to both understand and treat immune-based diseases.

Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2001 and we look forward to seeing you at our 18th Annual Meeting in San Francisco, California!  

Visit the FOCIS 2018 microsite to view the program, register, book a room and more!

JanssenImmunologyFocisBanner 

News & Information

FOCIS 2018 Registration, Housing and Abstract Submission are Now Open!

FOCIS2018 Nav Button 255x96-01

View the Preliminary Program
Take a look at the innovative lineup of topics and presenters on the FOCIS 2018 preliminary program. Additional presenters and topics will be announced as they are confirmed, so stay tuned!

Submit an Abstract
Submit your science to FOCIS 2018! Share your findings in front of leading clinicians and researchers in immunology. Abstracts are presented during Thematic Symposia, Oral Abstract Sessions, and at the evening Poster Sessions.

Register Now
Register today for THE meeting that will give you a competitive edge in your career. FOCIS registration includes more than 20 scientific sessions with more than 50 top clinicians and researchers from around the globe, speaking on cutting-edge topics across immunology and its related fields.

Book Your Hotel Room
FOCIS 2018 will be held at the San Francisco Marriott Marquis, located downtown in the South of Market (SoMa) neighborhood. Stay where all the action is! FOCIS has negotiated a special rate for FOCIS delegates of $299/night. Discounted trainee rooms are available for $209/night. Book your room today!

See you in San Francisco! #FOCIS

Success for FOCIS goes South: First FOCIS Workshop in Latin America

Immunotherapy journal cover imageFCE and regional researchers brought together in Santiago de Chile during May 15th-17th to present current scenarios and challenges in immunology. The Workshop "FOCIS goes South: Advances in Translational and Clinical Immunology" was organized by the FCE Millennium Institute on Immunology and Immunotherapy at the Pontificia Universidad Católica de Chile and gathered scientists from USA, France, Argentina, Brazil, Chile, Uruguay and Mexico, among others.

Read the success of 'FOCIS goes south: advances in translational and clinical immunology' in the Immunotherapy journal, VOL. 9, NO. 10

The inauguration ceremony of the Workshop was presided by the President of the Pontificia Universidad Católica de Chile, Dr. Ignacio Sánchez, the Minister of Economy, Natalia Piergentili, Senator Guido Girardi, the Director of Energy, Science, Technology and Innovation at the Ministry of Foreign Affairs, Ambassador Gabriel Rodríguez, FOCIS Multi-national FCE Chair, Dr.Ignacio Anegon, the Director of the Millennium Institute on Immunology and Immunotherapy (MIII), Dr. Alexis Kalergis, Associate Researcher at MIII and one of the organizers of the Meeting, Dr. Pablo González.

Read more...

All Articles...

 Immuno-Oncology Research Tools from BioLegend

 FOCIS 2017 Sponsors

 Graphic of FOCIS 2017 Supporters

 

 Preview of the latest ePublication

ePub header 2016

May 15, 2017
 
EDITOR: Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital  EDITORIAL BOARD: Abul K. Abbas, MD, University of California, San Francisco | Carla J. Greenbaum, MD, Benaroya Research Institute | Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital

Highlights from Recent Literature

circlearrow2 Help Not Wanted in the Joint
 

NEW! The 'Highlights from Recent Literature' review articles are now published monthly on Science Immunology under the "Editor's Choice" article category.

readmore

 
  Reviewed by Andrew H. Lichtman, Brigham and Women's Hospital

 

Developments in Basic Immunology and Novel Therapies

circlearrow2 Adoptive Cell Therapy with CAR-T cells: Rationale, Promise and Challenges
 

 

The idea of treating cancer patients by giving them large numbers of tumor-specific immune cells has been an appealing strategy of cancer immunotherapy for over two decades. The initial approaches relied on isolating rare circulating or tumor-infiltrating T cells (and, in some cases, natural killer [NK] cells) from patients, expanding these cells in culture, and injecting them back into the patients. Such treatments were successful in eliminating tumors in some patients, principally melanoma, but the results have been variable and often disappointing. There are many possible explanations for the modest success of passive immunity conferred by T cells. One important reason may be that in the cell populations used, the frequency of T cells that are specific for the tumor is low, and most of the transferred cells are not doing what it was hoped they would do. In addition, recovery of tumor-specific T cells is higher from certain tumor types such as melanoma, and lower in other tumors, limiting source materials (1).

readmore

 
  Submitted by Abul K. Abbas, MD, and Jonathan H. Esensten, MD, PhD, University of California, San Francisco

 

Human Immunophenotyping Update

circlearrow2 Sample Saving Technologies and Chip Flow Cytometry
 

The ever-expanding number of biomarkers, the drive towards precision medicine, the increasing awareness of cellular heterogeneity, and the interest in rare subsets of cells have, in combination, led to a pressing need to be able to perform various assays on sample of limited sizes or of low cellularity. In general, this is being accomplished by performing multiple assays on a single sample (multiplexing) or miniaturizing the technologies and assays, or both.

readmore

 
  Submitted by J. Philip McCoy, Jr., PhD, NHLBI, National Institutes of Health

Selected Recent Clinical Trial Results

circlearrow2 Safety and Tolerability of an ANTI-CD19 MONOCLONAL Antibody, MEDI-551, in Subjects with Systemic Sclerosis: A Phase I, Randomized, Placebo-controlled, Escalating Single-dose Study
 

Clinical Trial: Schiopu E, Chatterjee S, Hsu V, et al. Arthritis Res Ther. 2016 Jun 07; 18(1):131

Disease: limited or diffuse cutaneous systemic sclerosis (SSc)

Intervention: MEDI-551, an anti-CD19 monoclonal antibody 

readmore

 
  Submitted by Sandra Lord, MD, Benaroya Research Institute. Edited by Carla J. Greenbaum, MD, Benaroya Research Institute


   

Share